Asset Details
Do you wish to reserve the book?
CaMK II in Cardiovascular Diseases, Especially CaMK II-delta: Friends or Enemies
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
CaMK II in Cardiovascular Diseases, Especially CaMK II-delta: Friends or Enemies
Do you wish to request the book?
CaMK II in Cardiovascular Diseases, Especially CaMK II-delta: Friends or Enemies
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
CaMK II in Cardiovascular Diseases, Especially CaMK II-delta: Friends or Enemies
2024
Overview
Cardiovascular diseases (CVDs) tend to affect the young population and are associated with a significant economic burden and psychological distress to the society and families. The physiological and pathological processes underlying CVDs are complex. [Ca.sup.2+]/calmodulin-dependent kinase II (CaMK II), a protein kinase, has multiple biological functions. It participates in multiple pathological processes and plays a central role in the development of CVDs. Based on this, this paper analyzes the structural characteristics and distribution of CaMK II, the mechanism of action of CaMK II, and the relationship between CaMK II and CVDs, including ion channels, ischemia-reperfusion injury, arrhythmias, myocardial hypertrophy, cardiotoxicity, hypertension, and dilated cardiomyopathy. Given the different regulatory mechanisms of different isoforms of CaMK II, the clinical use of specific targeted inhibitors or novel compounds should be evaluated in future research to provide new directions. Keywords: CaMK II, cardiovascular diseases, ischemia-reperfusion injury, arrhythmias, myocardial hypertrophy
Publisher
Dove Medical Press Limited
Subject
We currently cannot retrieve any items related to this title. Kindly check back at a later time.